Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernd Wullich

Showing results (171-180 of 251) with videos related to

Pageof 26
Sort By:
Genes|February 10, 2021
<i>TERT</i> Promoter Mutation Analysis of Whole-Organ Mapping Bladder CancersVeronika Weyerer, Markus Eckstein, Pamela L Strissel, et al.
BMC Cancer|December 19, 2014
Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasisSusanne Fuessel, Kati Erdmann, Helge Taubert, et al.
Cancers|May 21, 2020
CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node StageMarkus Eckstein, Elena Epple, Rudolf Jung, et al.
European Urology Open Science|June 16, 2025
Clinical and Genomic Landscape of <i>FGFR3</i> Alterations Across Different Stages of Urothelial CancerMaximilian Haas, Roman Mayr, Danijel Sikic, et al.
Cancers|September 19, 2020
Expression of AR-V7 (Androgen Receptor Variant 7) Protein in Granular Cytoplasmic Structures Is an Independent Prognostic Factor in Prostate Cancer PatientsPaul König, Markus Eckstein, Rudolf Jung, et al.
Life (Basel, Switzerland)|May 28, 2022
Combined miR-486 and GP88 (Progranulin) Serum Levels Are Suggested as Supportive Biomarkers for Therapy Decision in Elderly Prostate Cancer PatientsAlexander Fichte, Angela Neumann, Katrin Weigelt, et al.
Cells|January 20, 2021
Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant ChemotherapyHelge Taubert, Markus Eckstein, Elena Epple, et al.
Cancer Research|January 21, 2021
Bladder Tumor Subtype Commitment Occurs in Carcinoma <i>In Situ</i> Driven by Key Signaling Pathways Including ECM RemodelingAdrian Wullweber, Reiner Strick, Fabienne Lange, et al.
JCO Oncology Practice|June 7, 2024
A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation CenterLisa Cuba, Pauline Dürr, Katja Gessner, et al.
Prostate Cancer|February 7, 2017
Analysis of Argonaute Complex Bound mRNAs in DU145 Prostate Carcinoma Cells Reveals New miRNA Target GenesJaroslaw Szczyrba, Volker Jung, Michaela Beitzinger, et al.
Pageof 26

Showing results (171-180 of 251) with videos related to

Sort By:
Pageof 26
Genes|February 10, 2021
<i>TERT</i> Promoter Mutation Analysis of Whole-Organ Mapping Bladder CancersVeronika Weyerer, Markus Eckstein, Pamela L Strissel, et al.
BMC Cancer|December 19, 2014
Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasisSusanne Fuessel, Kati Erdmann, Helge Taubert, et al.
Cancers|May 21, 2020
CCL2 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Shows Divergent Prognostic Potential for Bladder Cancer Patients Depending on Lymph Node StageMarkus Eckstein, Elena Epple, Rudolf Jung, et al.
European Urology Open Science|June 16, 2025
Clinical and Genomic Landscape of <i>FGFR3</i> Alterations Across Different Stages of Urothelial CancerMaximilian Haas, Roman Mayr, Danijel Sikic, et al.
Cancers|September 19, 2020
Expression of AR-V7 (Androgen Receptor Variant 7) Protein in Granular Cytoplasmic Structures Is an Independent Prognostic Factor in Prostate Cancer PatientsPaul König, Markus Eckstein, Rudolf Jung, et al.
Life (Basel, Switzerland)|May 28, 2022
Combined miR-486 and GP88 (Progranulin) Serum Levels Are Suggested as Supportive Biomarkers for Therapy Decision in Elderly Prostate Cancer PatientsAlexander Fichte, Angela Neumann, Katrin Weigelt, et al.
Cells|January 20, 2021
Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant ChemotherapyHelge Taubert, Markus Eckstein, Elena Epple, et al.
Cancer Research|January 21, 2021
Bladder Tumor Subtype Commitment Occurs in Carcinoma <i>In Situ</i> Driven by Key Signaling Pathways Including ECM RemodelingAdrian Wullweber, Reiner Strick, Fabienne Lange, et al.
JCO Oncology Practice|June 7, 2024
A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation CenterLisa Cuba, Pauline Dürr, Katja Gessner, et al.
Prostate Cancer|February 7, 2017
Analysis of Argonaute Complex Bound mRNAs in DU145 Prostate Carcinoma Cells Reveals New miRNA Target GenesJaroslaw Szczyrba, Volker Jung, Michaela Beitzinger, et al.
Pageof 26